A new cancer drug, Defactinib (VS-6033), is an orally administered compound designed to target and kill cancer cells in mesothelioma patients. The clinical trial named COMMAND (Control of Mesothelioma and Maintenance Defactinib) is a global clinical trial involving...
Clinical trials may provide treatment for mesothelioma patients that is not available from their physician. Clinical trials are research studies involving people based on scientific research with strict guidelines and limitations. These trials are regulated by the...
Mesothelioma patients may benefit from the results of the clinical trials being conducted at Memorial Sloan-Kettering Cancer Center in New York. Recently, researchers have tested a Wilms Tumor-1 (WT1) vaccine to see if it delays or prevents malignant pleural...
Patients suffering from mesothelioma, lung cancer, and other solid tumors may be eligible to participate in clinical trials at the National Cancer Institute (NCI) in Bethesda Maryland involving the use of immunotherapy agents which target the tumor antigen mesothelin....
Last week researchers reported that another important biomarker has been identified for treating mesothelioma and lung cancer patients. Researchers have discovered that the fibroblast growth-inducible 14 (FN14) gene plays a role in tumor growth and metastasis. When...
Subscribe To This Blog’s Feed